Compare WSR & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSR | IRWD |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 775.0M | 741.8M |
| IPO Year | 2002 | 2009 |
| Metric | WSR | IRWD |
|---|---|---|
| Price | $15.96 | $3.48 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.50 | $4.94 |
| AVG Volume (30 Days) | 181.7K | ★ 2.8M |
| Earning Date | 06-01-2026 | 05-26-2026 |
| Dividend Yield | ★ 3.79% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | ★ 0.52 | 0.15 |
| Revenue | $154,282,000.00 | ★ $298,276,000.00 |
| Revenue This Year | $0.31 | $57.95 |
| Revenue Next Year | $4.07 | $4.39 |
| P/E Ratio | $28.83 | ★ $24.03 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $11.43 | $0.55 |
| 52 Week High | $15.50 | $5.78 |
| Indicator | WSR | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 69.07 | 38.14 |
| Support Level | $11.86 | $3.08 |
| Resistance Level | N/A | $3.53 |
| Average True Range (ATR) | 0.34 | 0.35 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 94.93 | 27.27 |
Whitestone REIT is a real estate investment trust (REIT) engaged in owning and operating commercial properties in culturally diverse markets in metropolitan areas. The company's primary business objective is to increase shareholder value by acquiring, owning, and operating Community Centered Properties. Its property portfolio includes retail and mixed-use properties located in business friendly locations in and around Austin, Chicago, Dallas-Fort Worth, Houston, Phoenix, and San Antonio. The properties are convenience-focused: merchandised with a mix of service-oriented tenants providing food (restaurants and grocers), self-care (health and fitness), services (financial and logistics), education, and entertainment to the surrounding communities.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.